Below are links to copies of U.S. government contracts for technologies to combat the COVID-19 pandemic. KEI is updating this page as we have access to more contracts and fewer edited versions. Agreements related to the Medical CBRN Defense Consortium (MCDC), whose agreements are signed by Advanced Technology International (ATI), are marked “(via ATI)”. “We thank the Government of Canada for its confidence in our program and for its continued partnership in the regulatory review and delivery of a safe and effective COVID-19 vaccine to the citizens of Canada,” said John J. Trizzino, Novavax`s Chief Business Officer and Chief Business Officer. “Novavax is proud to do its part to work tirelessly with governments, scientists, regulators and other stakeholders to end the pandemic. The federal government has been working since the beginning of the pandemic to develop, manufacture and distribute safe and effective COVID-19 vaccines. The Government of Canada will continue to ensure access to safe and effective COVID-19 vaccines. Canada has secured COVID-19 vaccines from Pfizer and Moderna for 2022 and 2023, with options to extend until 2024. Some doses have been postponed from the original agreements to 2022.
When these agreements were signed, it was not clear which vaccine candidates would receive Health Canada approval and, if so, when they would. Production capacities and supply chains were also still under construction. The Government is also providing up to $23.2 million in funding through the National Research Council of Canada`s Industrial Research Assistance Program to advance six COVID-19 vaccine candidates at various stages of clinical trials. The Prime Minister, Justin Trudeau, today announced an investment of up to $173 million through the Strategic Innovation Fund (SIF) in Medicago, Quebec City, to support Canada`s COVID-19 response and future preparedness. The $428 million project will advance Medicago`s viral-like particle vaccine, developed on the company`s unique plant production platform, through clinical trials. It will also build a large vaccine and antibody production facility to increase Canada`s domestic bioproduction capacity. In addition to providing booster doses, the agreements provide flexibility in purchasing new second-generation COVID-19 vaccine adaptations, by . B to protect against mutations or variants of concern, and vaccines designed for younger populations. The government has signed an agreement with Medicago to obtain up to 76 million doses of its COVID-19 vaccine candidate, enough to vaccinate 38 million people. This is the first vaccine candidate developed in the country and obtained by the Canadian government. This approach allows us to share as much information as possible without compromising our existing agreements or our ability to keep Canadians safe. “Our government continues to manage the effects of the pandemic while preparing for future waves.
Today`s investment is helping Canadian companies PNI and Medicago further develop the Canadian-made vaccine candidates recommended by the COVID-19 Vaccine Working Group and support researchers and companies helping to fight this pandemic. This is all part of our Government`s ongoing commitment to protecting the health and safety of all Canadians. To ensure the equitable distribution of COVID-19 vaccines, the federal government has launched programs to directly and quickly reach high-risk communities. About NovavaxNovavax, Inc. (Nasdaq: NVAX) is an advanced biotechnology company that promotes improved health worldwide through the discovery, development and commercialization of innovative vaccines for the prevention of serious infectious diseases. The company`s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles tailored to urgent global health needs. .